A TOPAZ-1 post hoc analysis found that patients with biliary tract cancer with clinically actionable genomic alterations, including FGFR2 rearrangements, had an OS benefit from first-line durvalumab plus gemcitabine and cisplatin versus chemotherapy alone.44 This evidence concerns the gene FGFR2 and biliary tract cancer.